NCI Initiates Study Of Novel Imaging Techniques To Identify Precursor Stages Of Myeloma – The National Cancer Institute (NCI) is recruiting patients for a study investigating the use of sensitive imaging technologies to identify progression of myeloma precursor diseases. There are currently no diagnostic tests available to determine whether an individual with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma will develop multiple myeloma. New and improved imaging techniques may help physicians better detect the progression of these precursor diseases. This trial is recruiting participants with MGUS, smoldering myeloma, or myeloma. For more information, see the clinical trial ^[1] description. To participate in the trial, please contact the research nurse, Mary Ann Yancey, at (301) 435-9227 or .

Phase 2 Trials Of IPH 2101 Are Recruiting Myeloma And Smoldering Myeloma Patients – Several Phase 2 clinical trials are now recruiting multiple myeloma and smoldering multiple myeloma patients to receive the experimental agent IPH 2101 ^[2] (anti-KIR). IPH 2101 is an antibody drug being developed by Innate Pharma ^[3]. It helps activate cells of the immune system to destroy cancer cells. IPH 2101 is being studied in patients with smoldering myeloma to see if it delays and/or prevents progression to multiple myeloma (trial description ^[4]). It is also being studied in multiple myeloma patients in stable partial response after a first line therapy (trial description ^[5]) and in combination with Revlimid ^[6] (lenalidomide) in myeloma patients experiencing their first relapse (trial description ^[7]). To participate in the smoldering myeloma trial at the National Institutes of Health, please contact the research nurse, Mary Ann Yancey, at (301) 435-9227 or .

Phase 3 Double Transplant Trial Is Currently Recruiting Myeloma Patients – Myeloma patients are now being recruited by the Hackensack University Medical Center in New Jersey to participate in a Phase 3 trial of tandem stem cell transplants with melphalan ^[8] (Alkeran) followed by melphalan and Velcade ^[9] (bortezomib). The purpose of this trial is to determine if the addition of Velcade to the second transplant will increase remission times. For more information, please see the clinical trial ^[10] description.